WARREN, R. B.; REICH, K.; SIMPSON, E. L.; LANGLEY, R.; COSTANZO, A.; SAEKI, H.; ALMGREN, P.; VACKO, E.; GOODERHAM, M.; DELEURAN, M.; FRANCISCO SILVESTRE, J.; WEIDINGER, S.; BLAUVELT, A. 3 years of tralokinumab treatment provides long-term disease control as demonstrated by clinically meaningful outcomes in moderate-to-severe atopic dermatitis. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 6, n. 6, p. s78, 2022. DOI: 10.25251/skin.6.supp.78. Disponível em: https://jofskin.org/index.php/skin/article/view/1836. Acesso em: 22 jul. 2024.